Staff Profiles
Professor John Isaacs
Professor of Clinical Rheumatology
- Email: john.isaacs@ncl.ac.uk
- Telephone: +44 (0) 191 208 5337
- Address: 4th Floor, William Leech Building
Medical School
Framlington Place
Newcastle upon Tyne
NE2 4HH
Background
My team’s work is focussed in two major areas:
· The development and testing of novel immunotherapies for autoimmunity, with a particular interest in therapeutic tolerance induction.
· Rheumatoid arthritis – immunopathogenesis, biomarkers and novel therapeutic strategies including treatment stratification
Major current therapeutic projects include the development of an autologous tolerogenic dendritic cell therapy for rheumatoid arthritis (AUTODECRA, funded by Versus Arthritis ); the first ever clinical trial of a drug targeted at the synovial fibroblast in rheumatoid arthritis (TRAFIC, funded by the Medical Research Council); an experimental medicine study to identify the biological factors that underpin disease flare in rheumatoid arthritis (BIO-FLARE, funded by the Medical Research Council); we are also part of an EU Innovative Medicines Initiaitive, Rheumatherapy-Cure (RT-CURE), which aims to prevent rheumatoid arthritis by targeting ‘at risk’ individuals with tolerogenic therapies.
Therapeutic tolerance induction remains a ‘holy grail’ for human autoimmunity although there is now a concerted international effort to demonstrate that this is an achievable aim. A major limitation is a lack of understanding of the immune dysregulation inherent in most human autoimmunity, and consequent lack of ‘tolerance biomarkers’. These are essential in order to conduct rational therapeutic tolerance trials. This is a key aim of the MRC/ABPI Immunology and Inflammation Initiative for inflammatory arthritis, RA-MAP, for which I am Chief Investigator. By performing a systems immunology analysis of a cohort of patients with early rheumatoid arthritis, we will dissect the immunopathogenesis of the disease which, in turn, will provide key biomarkers.
All of our work is supported by cutting edge facilities, including the state-of-the art Wilson Horne Immunotherapy Centre and Versus Arthritis Experimental Arthritis Treatment Centre, a clinical research facility dedicated to the investigation of novel immunotherapies which incorporates arthroscopy and high resolution ultrasound scanning. We are a member of the NOCRI Translational Research Collaboration for inflammatory arthritis, for which I was the inaugural national lead. Our laboratory is based in recently refurbished, open plan laboratory facilities alongside other internationally renowned immunology researchers. I am also a principal investigator of the Versus Arthritis Centre of Excellence in Rheumatoid Arthritis Pathogenesis, alongside colleagues in Glasgow (PI Iain McInnes) and Birmingham (PI Chris Buckley)
Local roles:
- Professor of Clinical Rheumatology
- Director, Therapeutics North East
- Deputy Director, NIHR Newcastle Biomedical Centre for Ageing and Long-Term Conditions.
- Director of Research/Associate Medical Director, Newcastle Hospitals NHS Trust
- Director, Newcastle Biomedicine Versus Arthritis Experimental Arthritis Treatment Centre
- Director, Wilson Horne Immunotherapy Centre
- Consultant Rheumatologist, Newcastle upon Tyne Hospitals NHS Foundation Trust
National and International roles:
2018-20 - Scientific Chair, European League Against Rheumatism (EULAR)
2020-21 - Member, UKRI/ DHSC Oversight Committee for Covid-19 Immunology in the UK
2019-23 - NIHR Senior Investigator
2018 - MRC Precision Medicine Group
2017 – Versus Arthritis Fellowships Expert Advisory Group
2016 – Member, NIHR/NOCRI Translational Research Collaboration for Inflammatory Disease
2014 - Member, MRC Translational Research Group
Google Scholar: Click here.
Research
CURRENT MAJOR RESEARCH PROJECTS:
TRAFIC
This project aims to repurpose a small molecule anti-cancer drug as an anti-fibroblast drug for RA. The past 20 years have seen major advances in RA therapy; more aggressive use of conventional drugs, and biological targeted therapies have each made a significant impact. However, disease remission remains uncommon and around 20% of patients remain refractory to all therapies. This represents a significant unmet need and suggests key aspects of RA pathogenesis remain untargetted.
In health, a delicate nutritive synovial membrane (SM) lines joint cavities. This comprises a few macrophages and fibroblasts in a loose connective tissue stroma. In RA the SM is the focus of autoimmune attack but, in addition to inflammatory cell infiltration, resident synovial fibroblasts (SF) become hyperplastic, forming a vascularised, inflammatory, quasi-malignant pannus which invades articular cartilage and bone. The resultant joint damage underlies the disability and reduced quality of life that characterise RA.
Cell proliferation relies on the coordinated activation of specific regulatory proteins: orderly progression through the cell cycle is tightly controlled by the formation and activation of complexes comprising cyclin proteins and cyclin-dependent kinases (CDK). These complexes are in turn regulated by endogenous CDK inhibitors (CDKI). The concept of inhibiting CDKs to correct uncontrolled cell proliferation has led to the evaluation of small molecule CDKI in cancer.
RA SF have reduced endogenous CDKI levels, and correction of the deficit normalises their dysregulated phenotype. Indeed, small molecule CDKI ameliorate synovitis in pre-clinical arthritis models. In partnership with the SME Cyclacel, we propose a phase IIa repurposing study of a CDKI in patients with refractory RA. Stage 1 will focus on safety and tolerability, to determine an appropriate dose to progress to stage 2, where we will seek evidence of potential therapeutic activity alongside PK and PD biomarkers.
BIO-FLARE
Flares of immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA), are a major burden for patients. They occur unpredictably, adding to the physical and psychological burden of the condition, and contribute to joint damage and comorbidities, such as cardiovascular disease. Flares are difficult to study, precisely because of their unpredictable timing. However, we have established a human model that generates a 'synchronized' population of RA patients in clinical remission, of whom about 50% flare within 6 months, the remainder maintaining remission. We propose to carefully study such a population to better understand the factors that determine disease flare.
Up to a third of patients with RA achieve disease remission with aggressive therapy. Many wish to discontinue therapy at this point and, if they do, about 50% flare in the subsequent 6 months. We will follow such a population pr ospectively, to study the biological processes underpinning flare. We will study 150 patients in clinical remission for at least 6 months, and prepared to discontinue treatment. After treatment cessation patients will be studied intensively, with blood sampling at weeks 2, 4, 6, 12 and 24. Patients will also undergo ultrasound-guided biopsy of 'flaring' synovium before reinstatement of previous treatment (with which patients readily regain remission). We will also obtain biopsies from consenting patients at baseline and in remission at 6 months.
In blood we will study immune cell subsets and their activation status; autoantibody profiles; and epigenetic profiles. Synovial biopsies will allow us to examine the cell lineages present, including stromal cell subtypes, as well as inflammatory mediators. We will additionally examine metabolic profiles in blood, urine and synoivum.
Using multivariate statistical techniques we will develop a model that predicts impending flare in RA, highlighting tractable therapeutic pathways and informative biomarkers.
AUTODECRA-2
AuToDeCRA-2 addresses two critical aspects of tolDC therapy: the route of tolDC administration and the demonstration of specific immune modulation. Our hypothesis is that tolDC will need to access seondary lymphoid tisses in order to modulate the autoreactive immune response.
We wish to identify an optimal route for tolDC administration. This should be technically practical, and enable tolDC to reach spleen, liver or lymph nodes (alone or in combination). TolDC will be labelled with a 'dye' that is visible by MRI, and loaded with cirullinated peptides prior to administration. We will then apply cutting edge immunological assays, using MHC-peptide tetramers, to identify and phenotype autoreactive T-cells, ultimately associating tolDC distribution with immune modulation.
We will study 16 patients with anti-citrullinated peptide autoantibody (ACPA) positive RA. They will be HLADR*0401 or *0404 positive and receiving non-biologic) DMARD therapy. TolDC will be manufactured according to the protocols we have developed over the past ten years, and used for AuToDeCRA-1. However, tolDC will be labelled with 19F, a stable and non-radioactive isotope that can be sensitively tracked using MRI. Additionally, tolDC will be loaded with a mixture of citrullinated peptides. 19F-cit-tolDC will be injected via three distinct routes: intradermal; intra-articular; and intra-nodal. Control groups will receive intra-nodal 19F-tolDC that have not been loaded with citrullinated peptides.
MRI will be performed immediately after tolDC administration, 24 and 72 hours later. Blood for immune monitoring will be taken at baseline, 1, 2, 6 and 13 weeks after treatment. Specific immune monitoring will utilise anti-citrullinated peptide autoantibody profiling, alongside enumeration and functional analysis of antigen-specific T-cells, identified by appropriate MHC-peptide tetramers (derived from the peptides used to load tolDC). We will study autoreactive T-cell proliferation, surface phenotype, cytokine production and transcriptional profiling. Our final analysis will compare the distribution of tolDC after administration with evidence of subsequent immune modulation. We will also record disease activity and carefully document potential adverse effects.
RA-MAP
Our primary aim is to identify clinical, molecular and cellular biomarkers of prognosis and therapeutic response in patients with early rheumatoid arthritis (RA). Clinical predictors will be identified principally from meta-analysis of data derived from the placebo arms of completed clinical trials, seeking baseline parameters that associate with subsequent clinical response. Additional clinical predictors will be identified from an inception cohort of patients with early RA, followed longitudinally (the TACERA study). These patients will also provide the substrate to identify molecular and cellular biomarkers of prognosis and therapeutic response: participants will donate blood and urine at 3 monthly intervals for transcriptomic, flow cytometric, epigenetic, proteomic and metabolomic analyses. A systems based immunology approach will be adopted to identify baseline parameters that predict 6 month outcomes. By comparison with equivalent molecular profiles obtained from healthy individuals we will seek to define elements of immune dysregulation in RA and address whether the immune system of patients who subsequently achieve remission reverts to normal or continues to manifest immune dysregulation. A parallel study will similarly analyse blood samples from vaccinated healthy individuals, to compare the immune dysregulation in RA with the evolving response to vaccination. Ultimately, molecular or cellular biomarkers that inform prognosis or therapeutic response will be developed into a data warehouse and ‘polyomic toolkit’ describing the hallmarks of RA in blood, to enable the development of in vitro assays for patient monitoring.
A secondary aim of the programme is to identify individuals at high risk of developing RA, in order to evaluate immunological factors associated with the ‘pre-RA’ state.
Publications
- Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs JD, Kone-Paut I, Magro-Checa C, Mcinnes I, Meroni PL, Quartuccio L, Ramanan AV, Ramos-Casals M, Rodriguez Carrio J, Schulze-Koops H, Stamm TA, Tas SW, Terrier B, Mcgonagle DG, Mariette X. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases 2021, 80(6), 698-706.
- Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nature Reviews Rheumatology 2021, 17(2), 81-97.
- Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romao VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Canete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C, Thompson C, Bugatti S, Bellan M, Congia M, Holroyd C, Pratt A, Cabral da Fonseca JE, White L, Warren L, Peel J, Hands R, Fossati-Jimack L, Hadfield G, Thorborn G, Ramirez J, Celis R. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. The Lancet 2021, 397(10271), 305-317.
- Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive Diseases and Sciences 2021, 66, 2732-2743.
- Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials (Digestive Diseases and Sciences, (2020), 10.1007/s10620-020-06560-4). Digestive Diseases and Sciences 2021, 66, 3214-3215.
- Landewe RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A, Isaacs JD, Mariette X, McInnes I, Mueller-Ladner U, Openshaw P, Smolen JS, Stamm TA, Wiek D, Schulze-Koops H. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases 2020, 79(7), 851-858.
- Tarn JR, Lendrem DW, Isaacs JD. In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. Expert Review of Clinical Immunology 2020, 16(6), 621-630.
- Mehta P, Sanchez E, Moraitis E, Longley N, Lendrem DW, Giles IP, Chambers RC, Ciurtin C, Isaacs JD. Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. The Lancet Rheumatology 2021, 3(1), e9-e10.
- Baker KF, Thompson B, Lendrem DW, Scadeng A, Pratt AG, Isaacs JD. Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. Therapeutic Advances in Musculoskeletal Disease 2020, 12.
- Clark AD, Nair N, Anderson AE, Thalayasingam N, Naamane N, Skelton AJ, Diboll J, Barton A, Eyre S, Isaacs JD, Pratt AG, Reynard LN. Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci. Journal of Allergy and Clinical Immunology 2020, 145(5), 1438-1451.
- Gilani SSA, Nair N, Plant D, Hyrich K, Morgan AW, Morris AP, Wilson AG, Isaacs JD, Barton A, Bluett J. Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. Pharmacogenomics 2020, 21(16), 1151-1156.
- McMeekin P, Lendrem DW, Lendrem BC, Pratt AG, Peck R, Isaacs JD, Jones D. Schrödinger's pipeline and the outsourcing of pharmaceutical innovation. Drug Discovery Today 2020, 25(3), 480-484.
- Penkava F, Velasco-Herrera MDC, Young MD, Yager N, Nwosu LN, Pratt AG, Lara AL, Guzzo C, Maroof A, Mamanova L, Cole S, Efremova M, Simone D, Filer A, Brown CC, Croxford AL, Isaacs JD, Teichmann S, Bowness P, Behjati S, Hussein Al-Mossawi M. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nature Communications 2020, 11, 4767.
- Isaacs JD, Burmester GR. Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs. Annals of the Rheumatic Diseases 2020, 79(8), 991-993.
- Siebert S, Pratt AG, Stocken DD, Morton M, Cranston A, Cole M, Frame S, Buckley CD, Ng W-F, Filer A, McInnes IB, Isaacs JD. Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine 2020, 99(26), e20458.
- Mehta P, Porter JC, Manson JJ, Isaacs JD, Openshaw PJM, McInnes IB, Summers C, Chambers RC. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. The Lancet Respiratory Medicine 2020, 8(8), 822-830.
- Stanway JA, Isaacs JD. Tolerance-inducing medicines in autoimmunity: rheumatology and beyond. The Lancet Rheumatology 2020, 2(9), e565-e575.
- Baker KF, Isaacs JD, Thompson B. “Living a normal life”: a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis. BMC Rheumatology 2019, 3, 2.
- Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino M-A, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Ostor A, Raza K, Taylor PC, Van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials 2019, 20(1), 429.
- Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJH, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL, Kimberly RP, Okada Y, Van Riel PLCM, Wolbink G, Van Der Horst-Bruinsma IE, De Vries N, Tak PP, Ohmura K, Canhao H, Guchelaar H-J, Huizinga TWJ, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Annals of the Rheumatic Diseases 2019, 78(8), 1055-1061.
- Lendrem BC, Lendrem DW, Pratt AG, Naamane N, McMeekin P, Ng W-F, Allen AJ, Power M, Isaacs JD. Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic. Pharmaceutical Statistics 2019, 18(6), 632-635.
- Mousa AE, Okasha M, Isaacs JD, Price DA, Bhatnagar P, Joshi A, Surash S. Brain pseudotumour secondary to Behçet's disease. Annals of the Royal College of Surgeons of England 2019, 101(8), e164-e168.
- Romagnoni A, Jegou S, Van Steen K, Wainrib G, Hugot J-P, International Inflammatory Bowel Disease Genetics Consortium (IIBDGC), Clee CM, Ferrier IN, Isaacs JD, Mansfield J, Young AH. Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports 2019, 9(1), 10351.
- Anderson AE, Maney NJ, Nair N, Lendrem DW, Skelton AJ, Diboll J, Brown PM, Smith GR, Carmody RJ, Barton A, Isaacs JD, Pratt AG. Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. Rheumatology 2019, 58(7), 1250-1258.
- Ridgley LA, Anderson AE, Maney NJ, Naamane N, Skelton AJ, Lawson CA, Emery P, Isaacs JD, Carmody RJ, Pratt AG. IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function. Frontiers in Immunology 2019, 10, 1535.
- Strand V, Goncalves J, Hickling TP, Jones HE, Marshall L, Isaacs JD. Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. BioDrugs 2020, 34, 27-37.
- Coles AJ, Azzopardi L, Kousin-Ezewu O, Mullay HK, Thompson SAJ, Jarvis L, Davies J, Howlett S, Rainbow D, Babar J, Sadler TJ, Brown JWL, Needham E, May K, Georgieva ZG, Handel AE, Maio S, Deadman M, Rota I, Hollander G, Dawson S, Jayne D, Seggewiss-Bernhardt R, Douek DC, Isaacs JD, Jones JL. Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight 2019, 4(12), e125377.
- Wood MJ, Leckenby A, Reynolds G, Spiering R, Pratt AG, Rankin KS, Isaacs JD, Haniffa MA, Milling S, Hilkens CM. Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients. JCI Insight 2019, 4(2), e125325.
- Isaacs JD, Iqbal K. Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis. Clinical Therapeutics 2019, 41(7), 1312-1322.
- Baker KF, Skelton AJ, Lendrem DW, Scadeng A, Thompson B, Pratt AG, Isaacs JD. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. Journal of Autoimmunity 2019, 105, 102298.
- Iqbal K, Lendrem DW, Hargreaves B, Isaacs JD, Thompson B, Pratt AG. Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients. Rheumatology 2019, 58(7), 1268–1273.
- Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, Seror R, Skelton AJ, James K, McMeekin P, Al-Ali S, Hackett KL, Lendrem BC, Hargreaves B, Casement J, Mitchell S, Bowman SJ, Price E, Pease CT, Emery P, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Johnsen SJA, Norheim KB, Omdal R, Stocken D, Everett C, Fernandez C, Isaacs JD, Gottenberg J-E, Ng WF, French ASSESS cohort, UK Primary Sjogren's Syndrome Registry. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology 2019, 1(2), e85-e94.
- Spiering R, Jansen MAA, Wood MJ, Fath AA, Eltherington O, Anderson AE, Pratt AG, van Eden W, Isaacs JD, Broere F, Hilkens CMU. Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis. Journal of Translational Medicine 2019, 17, 375.
- Mosanya CH, Isaacs JD. Tolerising Cellular Therapies: What Is Their Promise for Autoimmune Disease?. Annals of the Rheumatic Diseases 2019, 78(3), 297-310.
- Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL. Biologic refractory disease in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases 2018, 77(10), 1405-1412.
- Thalayasingam N, Nair N, Skelton AJ, Massey J, Anderson AE, Clark AD, Diboll J, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Isaacs JD, Barton A, Pratt AG. CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification. Arthritis and Rheumatology 2018, 70(3), 361-370.
- Massey J, Plant D, Hyrich K, Morgan AW, Wilson AG, Spiliopoulou A, Colombo M, McKeigue P, Isaacs J, Cordell H, Pitzalis C, Barton A. Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. The Pharmacogenomics Journal 2018, 18(5), 657-664.
- Williams NH, Jenkins A, Goulden N, Hoare Z, Hughes DA, Wood E, Foster NE, Walsh D, Carnes D, Sparkes V, Hay EM, Isaacs J, Konstantinou K, Morrissey D, Karppinen J, Genevay S, Wilkinson C. Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC). Trials 2018, 19(1), 408.
- Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhauser M, Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grzes D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sanchez-Ramon S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum information about T regulatory cells: A step toward reproducibility and standardization. Frontiers in Immunology 2018, 8, 1844.
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. Annals of the Rheumatic Diseases 2018, 77(2), 175-187.
- Cooles FAH, Anderson AE, Skelton A, Pratt AG, Kurowska-Stolarska MS, McInnes I, Hilkens CMU, Isaacs JD. Phenotypic and transcriptomic analysis of peripheral blood plasmacytoid and conventional dendritic cells in early drug naïve rheumatoid arthritis. Frontiers in Immunology 2018, 9, 755.
- Jansen MAA, Spiering R, Broere F, van Laar JM, Isaacs JD, van Eden W, Hilkens CMU. Targeting of tolerogenic dendritic cells towards heat-shock proteins: A novel therapeutic strategy for autoimmune diseases?. Immunology 2018, 153(1), 51–59.
- Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-Del Mercado M, Andersson H, De Paepe B, DeBleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H, D'Hose S, Lu X, Tian X, Mann H, Krystufkova O, Plestilova L, Klein M, Barochova T, Kubinova K, Gelardi C, Pedini V, Cardinaletti P, Jara LJ, Saavedra MA, Cruz-Reyes CV, Vera-Lastra O, Andrade-Ortega L, Medrano-Ramirez G, Satoh M, Salazar-Paramo M, Gomez-Banuelos E, Aguilar-Arreola J, Duran-Barragan S, Navarro-Hernandez RE, Petri MH, Molberg O, Dastmalchi M, Notarnicola A, Gheorghe K, Ronnelid J, Liden M, Hanna B, Jalal A, Hellstrom H, Martineus JC, Lan NTN, Padyukov L, Platt H, Rothwell S, Ahmed Y, Armstrong R, Bernstein R, Black C, Bowman S, Bruce I, Butler R, Carty J, Chattopadhyay C, Chelliah E, Clarke F, Dawes P, Denton C, Devlin J, Edwards C, Emery P, Fordham J, Fraser A, Gaston H, Gordon P, Griffiths B, Gunawardena H, Hall F, Hanna M, Harrison B, Hay E, Hilton-Jones D, Horden L, Isaacs J, Isenberg D, Jones A, Kamath S, Kennedy T, Kitas G, Klimiuk P, Knights S, Lambert J, Lanyon P, Laxminarayan R, Lecky B, Luqmani R, Machado P, Marks J, Martin M, McGonagle D, McKenna F, McLaren J, McMahon M, McRorie E, Merry P, Miles S, Miller J, Nicholls A, Nixon J, Ong V, Over K, Packham J, Plant M, Pountain G, Pullar T, Roberts M, Sanders P, Scott D, Shadforth M, Sheeran T, Srinivasan A, Swinson D, The L-S, Webley M, Williams B, Winer J. The EuroMyositis registry: An international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases 2018, 77(1), 30-39.
- Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD, Anderson A, Stocks P, Lendrem D, Tarn J, Smith G, Casement J, Diboll J, Harry R, Simpson G, Toward R, Noble H, Parke A, Wu W, Clarke F, Scott D, Scott IC, Galloway J, Lempp H, Ibrahim F, Schwank S, Molyneux G, Lazarov T, Geissmann F, Donnelly I, Gilmour A, TulunayVirlan A, El-Jawhari J, Parmer R, Buch M, Buckley C, Young S, Jones P, Raza K, Filer A, Pitzalis C, Thorborn G, Fossati-Jimack L, Kelly S, Humby F, Novak T, Rana S, Goldmann K, Lewis M, Watson D, Jia Z, Altobelli G, John C, Martins S, Nguyen D, Ali H, Worthington J, Bruce I, Sergeant J, Verstappen S, D'Costa N, Stirling F, Hughes-Morley A, Farewell V, Zhong Y, Cuff C, Long A, Liu Z, Lipsky S, Harvey B, MacOritto M, Hong F, Kaymakcalan S, Sabin T, Ward N, Talbot S, Padhi D, Finch D, Herath A, Jenkins M, Ho M, Marshall C, Page M, Edwards H, Cuza A, Loza M, Curran M, Baker D, Vranic I, Mela CT, Wright S, Rowell L, Vernon E, Joseph N, Payne N, Ludbrook V, Hicks K, Tipney H, Ellis J, Hasan S, Didierlaurent A, Burny W, Haynes A, Larminie C, Dastros-Pitel D, Kola B, Jelinksy S, Hodge M, MacIejewski M, Ziemek D, Zucht H-D, Budde P. The RA-MAP Consortium: a working model for academia-industry collaboration. Nature Reviews Rheumatology 2018, 14(1), 53-60.
- Rayner F, Isaacs JD. Therapeutic tolerance in autoimmune disease. Seminars in Arthritis and Rheumatism 2018, 48(3), 558-562.
- Nikiphorou E, Mackie SL, Kirwan J, Boers M, Isaacs J, Morgan AW, Young A. Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. Rheumatology 2017, 56(4), 550-555.
- Bell GM, Anderson AE, Diboll J, Reece R, Eltherington O, Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl EM, Dunn J, Dickinson AM, Hilkens CMU, Isaacs JD. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Annals of the Rheumatic Diseases 2017, 76(1), 227-234.
- Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Annals of the Rheumatic Diseases 2017, 76(1), 4-6.
- Hanson H, O'Brien N, Whybrow P, Isaacs JD, Rapley T. Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in UK newspapers. Health Expectations 2017, 20(2), 309-320.
- Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, on behalf of BRAGGSS. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Annals of the Rheumatic Diseases 2017, 76(1), 208-213.
- Pollock J, Raza K, Pratt AG, Hanson H, Siebert S, Filer A, Isaacs JD, Buckley CD, Mcinnes IB, Falahee M. Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research. Musculoskeletal Care 2017, 15(4), 395-399.
- Baker KF, Pratt AG, Thompson B, Isaacs JD. Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. Annals of the Rheumatic Diseases 2017, 76(6), e12.
- Williams NH, Jenkins A, Goulden N, Hoare Z, Hughes DA, Wood E, Foster NE, Walsh DA, Carnes D, Sparkes V, Hay EM, Isaacs J, Konstantinou K, Morrissey D, Karppinen J, Genevay S, Wilkinson C. Subcutaneous injection of Adalimumab Trial compared with Control (SCIATiC): A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. Health Technology Assessment 2017, 21(60), 1-179.
- Orr C, Sousa E, Boyle DL, Buch MH, Buckley CD, Canete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SoA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ. Synovial tissue research: A state-of-the-art review. Nature Reviews Rheumatology 2017, 13(8), 463-475.
- Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, Isaacs JD. The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. Journal of Allergy and Clinical Immunology 2017, 141(1), 445-448.e4.
- Crosby D, Bossutt P, Brockehurst P, Chamberlain C, Dive C, Holmes C, Isaacs J, Kennedy R, Matthews F, Parmer M, Pearce J, Westhead D, Whittaker J, Holgate S. The MRC Framework for the Development, Design and Analysis of Stratified Medicine Research: Enabling Stratified, Precision and Personalised Medicine. London: Medical Research Council, 2017. Available at: https://www.mrc.ac.uk/research/initiatives/stratified-medicine/stratified-medicine-methodology-framework/.
- Smith SL, Plant D, Eyre S, Hyrich K, Morgan AW, Wilson AG, Isaacs JD, Barton A. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology 2017, 56(6), 1019-1024.
- Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby JA, Isaacs JD, Hilkens CM. Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T-cells partly via TGF-β1. Clinical & Experimental Immunology 2017, 187(1), 113-123.
- Cowell J, Buck M, Essa AH, Clarke R, Vollmer W, Vollmer D, Hilkens CM, Isaacs JD, Hall MJ, Gray J. Traceless-Cleavage of Protein-Biotin Conjugates Under Biologically-Compatible Conditions. ChemBioChem 2017, 18(17), 1688-1691.
- Pratt AG, Anderson AE, Carmody RJ, Isaacs JD. Bcl-3 in CD4+ T Cell–Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al. Arthritis and Rheumatology 2016, 68(3), 770-771.
- Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. Journal of Internal Medicine 2016, 279(1), 41-59.
- McGovern A, Schoenfelder S, Martin P, Massey J, Duffus K, Plant D, Yarwood A, Pratt AG, Anderson AE, Isaacs JD, Diboll J, Thalayasingam N, Ospelt C, Barton A, Worthington J, Fraser P, Eyre S, Orozco G. Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. Genome Biology 2016, 17, 212.
- Spyridopoulos I, Martin-Ruiz C, Hilkens C, Yadegarfar ME, Isaacs J, Jagger C, Kirkwood T, von Zglinicki T. CMV-seropositivity and T-cell senescence predict increased cardiovascular mortality in octogenarians - results from the Newcastle 85+ study. Aging Cell 2016, 15(2), 389-392.
- Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. Rheumatology 2016, 55(10), 1843-1848.
- McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nature Reviews Rheumatology 2016, 12(1), 63-68.
- Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A. Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. Rheumatology 2016, 55(11), 2050-2055.
- Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, Hyrich KL, Wilson AG, Morgan AW, Isaacs JD, Worthington J, Barton A. Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology 2016, 68(6), 1353-1360.
- Hanson H, Isaacs JD, Kay LJ, Lendrem DW, O'Brien N, Pratt AG, Rapley T. Experiences of staff and patients in relation to clinical research recruitment and involvement: a qualitative study. In: Rheumatology. 2016, Glasgow: Oxford University Press.
- Pratt AG, Massey J, Anderson AE, Nair N, Diboll J, Skelton A, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Barton A, Isaacs JD. Identification of novel expression quantitative trait loci in CD4+ T cells of untreated early arthritis patients. In: 36th European Workshop for Rheumatology Research. 2016, York: BMJ Group.
- Gavan S, Harrison M, Barton A, Hyrich K, Isaacs J, Morgan A, Wilson AG, Payne K. Identifying factors which influence the selection of anti-TNF treatment in patients with rheumatoid arthritis in England. In: ISPOR 21st Annual International Meeting. 2016, Washington, DC: Elsevier.
- Anderson AE, Pratt AG, Sedhom MA, Doran JP, Routledge C, Hargreaves B, Brown PB, LeCao KA, Isaacs JD, Thomas R. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anti-citrullinated peptide antibody-negative rheumatoid arthritis. Annals of the Rheumatic Diseases 2016, 75, 466-473.
- Cooles FAH, Anderson AE, Drayton T, Harry RA, Diboll J, Munro L, Thalayasingham N, Ostor AJK, Isaacs JD. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Research & Therapy 2016, 18, 302.
- Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology 2016, 12(12), 731-742.
- Lord P, Spiering R, Aguillón JC, Anderson AE, Appel S, Benitez-Ribas D, ten-Brinke A, Broere F, Cools N, Cuturi MC, Diboll J, Geissler EK, Giannoukakis N, Gregori S, van-Ham SM, Lattimer S, Marshall L, Harry RA, Hutchinson JA, Isaacs JD, Joosten I, van-Kooten C, López-Díaz-de-Cerio A, Nikolic T, Barbaros-Oral H, Sofronic-Milosavljevic L, Ritter T, Riquelme P, Thomson AW, Trucco M, Vives-Pi M, Martinez-Caceres E, Hilkens CM. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ 2016, 4, 1-14.
- Clowse MEB, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibille D, Chen Y, Frazier D, Geier J, Proulx J, Marren A. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety 2016, 39(8), 755-762.
- Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Barton A. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics 2016, 17(7), 715-720.
- Reynolds G, Gibbon JR, Pratt AG, Coady D, Raftery G, Lorenzi AR, Gray A, Filer A, Buckley CD, Haniffa MA, Isaacs JD, Hilkens CM. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Annals of the Rheumatic Diseases 2016, 75(5), 899-907.
- Lendrem DW, Lendrem BC, Linsley M, Rowland-Jones R, D'Agostino F, Owen MR, Isaacs JD. Teaching Examples for the Design of Experiments: Geographical Sensitivity and the Self-Fulfilling Prophecy. Pharmaceutical Statistics 2016, 15(1), 90-92.
- Baker KF, Thompson B, Lendrem DW, Pratt AG, Isaacs JD. Ultrasound measures of synovitis are independent of clinical parameters in the setting of rheumatoid arthritis remission: a cross-sectional analysis. In: 2016 Annual European Congress of Rheumatology. 2016, London, UK: BMJ Publishing Group.
- Reynolds G, Milne P, Bigley V, Collin M, Isaacs J, Hilkens C, Haniffa M. Use of the dendritic cell marker, B and T lymphocyte attenuator, to identify functionally distinct subsets of human CD1c+ dendritic cells. In: Spring Meeting for Clinician Scientists in Training 2016. 2016, London, UK: Elsevier.
- James K, Al-Ali S, Tarn J, Cockell SJ, Gillespie CS, Hindmarsh V, Locke J, Mitchell S, Lendrem D, Bowman S, Price E, Pease CT, Emery P, Lanyon P, Hunter JA, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, The UK Primary Sjögren’s Syndrome registry, Wipat A, Newton J, Jones DE, Isaacs J, Hallinan J, Ng W-F. A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome. PLoS ONE 2015, 10(12), e0143970.
- Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, Symmons DPM, Worthington J, Young A, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Raychaudhuri S, Barton A. Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. JAMA: The Journal of the American Medical Association 2015, 313(16), 1645-1656.
- Jani M, Chinoy H, Isaacs J, Morgan AW, Wilson A, Hyrich KL, Plant D, Barton A. Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA, USA: Wiley.
- Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich KL, Barton A. Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich KL, Barton A, Biology Rheumatoid Arthrit Genetic. Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. Arthritis & Rheumatology 2015, 67(8), 2011-2019.
- Pratt AG, Hargreaves B, Lendrem DW, Aslam O, Isaacs JD. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA, USA: John Wiley & Sons, Inc.
- Isaacs JD. Decade in review—clinical rheumatology: 10 years of therapeutic advances in the rheumatic diseases. Nature Reviews. Rheumatology 2015, 11(11), 628-630.
- Gunther C, Kind B, Reijns MAM, Berndt N, Martinez-Bueno M, Wolf C, Tungler V, Chara O, Lee YA, Hubner N, Bicknell L, Blum S, Krug C, Schmidt F, Kretschmer S, Koss S, Astell KR, Ramantani G, Bauerfeind A, Morris DL, Graham DSC, Bubeck D, Leitch A, Ralston SH, Blackburn EA, Gahr M, Witte T, Vyse TJ, Melchers I, Mangold E, Nothen MM, Aringer M, Kuhn A, Luthke K, Unger L, Bley A, Lorenzi A, Isaacs JD, Alexopoulou D, Conrad K, Dahl A, Roers A, Alarcon-Riquelme ME, Jackson AP, Lee-Kirsch MA. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. Journal of Clinical Investigation 2015, 125(1), 413-424.
- Gunther C, Kind B, Reijns MAM, Berndt N, Martinez-Bueno M, Wolf C, Tungler V, Chara O, Lee YA, Hubner N, Lee YA, Bicknell L, Blum S, Krug C, Schmidt F, Krug C, Kretschmer S, Koss S, Astell KR, Ramantani G, Bauerfeind A, Morris DL, Graham DSC, Bubeck D, Leitch A, Ralston SH, Blackburn EA, Gahr M, Witte T, Vyse TJ, Melchers I, Mangold E, Nothen MM, Aringer M, Kuhn A, Luthke K, Unger L, Bley A, Lorenzi A, Isaacs JD, Alexopoulou D, Conrad K, Dahl A, Roers A, Alarcon-Riquelme ME, Jackson AP, Lee-Kirsch MA. Defective removal of ribonucleotides from DNA promotes systemic lupus erythematosus. Pediatric Rheumatology 2015, 13(1).
- Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, Vlahos B, Hammond C, Bukowski J, Li HH, Schulman SL, Raber S, Zuckerman A, Isaacs JD. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Research & Therapy 2015, 17, 95.
- James K, Al-Ali S, Tarn J, Cockell SJ, Gillespie CS, Bowman S, Isaacs J, Jones DE, Newton J, Price E, Wipat A, Hallinan J, Ng WF, UKPSSR. Gene Set Enrichment Analysis Across Multiple Expression Studies Reveals a Core Subset of Primary Sjögren's Syndrome-Related Genes. In: The 13th International Symposium on Sjögren's Syndrome. 2015, Bergen, Norway: Wiley-Blackwell.
- Smith SL, Plant D, Eyre S, Hyrich KL, Morgan AW, Wilson GA, Isaacs J, Barton A. Genome-Wide Transcriptional Profiling of Rheumatoid Arthrits Patients: Towards Stratified Medicine. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Pratt AG, Isaacs JD. Genotyping in rheumatoid arthritis: a game changer in clinical management?. Expert Review of Clinical Immunology 2015, 11(3), 303-305.
- Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Cordingley L, Barton A, BRAGGSS. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology 2015, 54(3), 494-499.
- Smith SL, Eyre S, Yarwood A, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Plant D, Barton A, Biol Rheumatoid Arthrit Genetics. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. Arthritis Research & Therapy 2015, 17, 359.
- Hao CM, Plant D, Isaacs J, Hyrich KL, Morgan A, Wilson G, Barton A. Investigation of Genetic Variants in Predicting Response to Biologic Drugs Used to Treat Rheumatoid Arthritis. In: Rheumatology. 2015, Manchester, UK: Oxford University Press.
- Lendrem DW, Lendrem BC, Woods D, Rowland-Jones R, Burke M, Chatfield M, Isaacs JD, Owen MR. Lost in Space: Design of Experiments and Scientific Exploration in a Hogarth Universe. Drug Discovery Today 2015, 20(11), 1365-1371.
- Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, Symmons DPM, Worthington J, Young A, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Raychaudhuri S, Barton A. Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritis—Multi-Centre Prospective Cohort Studies. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Lendrem DW, Lendrem BC, Peck RW, Senn SJ, Day S, Isaacs JD. Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery 2015, 14, 219-221.
- Pratt AG, Hargreaves B, Routledge C, Tiffin L, Norris J, Humphrey C, Isaacs JD. Reasons for Treatment Delay in Early Rheumatoid Arthritis Differ According to Autoantibody Status. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Baker K, Isaacs J, Thompson B. Restoring or Threatening a Normal Life: Withdrawing Medication from Patients with Rheumatoid Arthritis in Remission. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Baker K, Isaacs J, Thompson B. Restoring or Threatening a Normal Life: Withdrawing Medication from Patients with Rheumatoid Arthritis in Remission. In: 2015 British Society of Rheumatology Annual Conference. 2015, Manchester, UK: Oxford University Press.
- Cooles FAH, Pratt AG, Lendrem DW, Ng WF, Aspray TJ, Isaacs JD. Retrospective analysis of the role of serum vitamin D in early rheumatic disease. Rheumatology 2015, 54(2), 374-375.
- Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Sema AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernandez-Nebro A, Ordonez MD, Narvaez J, Canete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG, Gomez-Reino JJ, Gonzalez A, BRAGGSS. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. Arthritis Research & Therapy 2015, 17, 63.
- Brown PM, Isaacs JD. Rheumatoid Arthritis: An Evolutionary Force in Biologics. Current Pharmaceutical Design 2015, 21(17), 2170-2178.
- Jopson L, Newton JL, Howel D, Palmer J, Isaacs J, Qian J, Wilkinson J, Blamire A, Floudas A, Jones DE. RITPBC: B-cell depleting therapy (RITUXIMAB) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. In: 50th Annual meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
- Jopson L, Newton JL, Palmer J, Floudas A, Isaacs J, Qian J, Wilkinson J, Trenell M, Blamire A, Howel D, Jones DE. RITPBC: B-Cell Depleting Therapy (rituximab) as a treatment for fatigue in Primary Biliary Cirrhosis: study protocol for a randomised controlled trial. BMJ Open 2015, 5(8), e007985.
- Pratt AG, Anderson AE, Lendrem DW, Skelton A, Massey J, Nair N, Diboll J, Hargreaves B, Brown PM, Barton A, Isaacs JD. STAT3-regulated gene expression in circulating CD4+ T cells discriminates RA patients independently of clinical parameters in early arthritis: a validation study. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA.
- Pratt AG, Anderson AE, Nair N, Massey J, Diboll J, Skelton A, Hargreaves B, Routledge C, Lendrem D, Brown P, Barton A, Isaacs JD. The Importance of IL-6-STAT3 Mediated Activation of Circulating CD4+ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Cooles FAH, Anderson AE, Hilkens C, Isaacs JD. The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA, USA: Wiley.
- Peck RW, Lendrem DW, Grant I, Lendrem BC, Isaacs JD. Why is it hard to terminate failing projects in pharmaceutical R&D?. Nature Reviews Drug Discovery 2015, 14, 1-2.
- Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens CMU. A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses. Journal of Immunology 2014, 193(3), 1142-1150.
- Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A, BRAGGSS. Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics Journal 2014, 14(2), 171-175.
- Bell G, Anderson AE, Diboll J, Harry R, McColl E, Dickinson A, Hilkens C, Isaracs JD. Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis. In: ACR/ARHP Annual Meeting. 2014, Boston, MA, USA: Wiley-Blackwell Publishing Ltd.
- Isaacs JD, Zuckerman A, Krishnaswami S, Nduaka C, Lan SP, Hutmacher MM, Boy MG, Kowalski K, Menon S, Riese R. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Research & Therapy 2014, 16(4), R158.
- Lendrem BD, Lendrem DW, Gray A, Isaacs JD. Christmas 2014: Going to Extremes. The Darwin Awards: sex differences in idiotic behaviour. BMJ 2014, 349, g7094.
- McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma SL, Schumacher MM, Bertolino AP, Hueber W, Tak PP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases 2014, 73(2), 349-356.
- Reynolds G, Cooles FAH, Isaacs JD, Hilkens CMU. Emerging immunotherapies for rheumatoid arthritis. Human Vaccines & Immunotherapeutics 2014, 10(4), 822-837.
- Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Annals of the Rheumatic Diseases 2014, 73(6), 1202-1210.
- Cordingley L, Prajapati R, Plant D, Maskell D, Morgan C, Ali FR, Morgan AW, Wilson AG, Isaacs JD, the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Barton A. Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. Arthritis Care & Research 2014, 66(6), 861-868.
- Baker KF, Isaacs JD. Prospects for therapeutic tolerance in humans. Current Opinion in Rheumatology 2014, 26(2), 219-227.
- Lendrem DW, Senn SJ, Lendrem BC, Isaacs JD. R&D Productivity Rides Again?. Pharmaceutical Statistics 2014.
- Brown PM, Isaacs JD. Rheumatoid arthritis: from palliation to remission in two decades. Clinical Medicine 2014, 14(Suppl. 6), s50-s55.
- Pratt AG, Isaacs JD. Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best Practice & Research Clinical Rheumatology 2014, 28(4), 651-659.
- Yarwood A, Viatte S, Plant D, Morgan AW, Isaacs J, Wilson AG, Hyrich K, Eyre S, Barton A. Testing the role of vitamin D in response to antitumour necrosis factor alpha therapy in a UK cohort: a Mendelian randomisation approach. Annals of Rheumatic Diseases 2014, 73(5), 938-40.
- Malaviya AP, Ledingham J, Bloxham J, Bosworth A, Buch M, Choy E, Cope A, Isaacs J, Marshall D, Wright G, Ostor AJ. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology 2014, 53(7), 1344-1346.
- Lendrem B, Lendrem DW, Gray A, Isaacs JD. The Darwin Awards: Gender Differences in Idiotic Behaviour. British Medical Journal 2014, 349, g7094.
- Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Annals of Rheumatic Disease 2013, 72(3), 329-336.
- Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Research & Therapy 2013, 15(6), R204.
- Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedren S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JBA, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PLCM, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TWJ, Toes REM, Kimberly RP, Bridges SL, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJH, Karlson EW, Plenge RM. Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics 2013, 9(3), e1003394.
- Richardson S, Isaacs J. Novel immunotherapies for rheumatoid arthritis. Clinical Medicine 2013, 13, 391-4.
- Pratt AG, Lorenzi AR, Wilson G, Platt PN, Isaacs JD. Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?. Arthritis Research & Therapy 2013, 15(5), R118.
- Cooles FAH, Pratt AG, Ng WF, Aspray TJ, Isaacs JD. The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis. In: ACR/ARHP Annual Meeting 2013. 2013, San Diego, CA, USA: Wiley-Blackwell.
- Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR. The role of biosimilars in the treatment of rheumatic diseases. Annals of the Rheumatic Diseases 2013, 72(3), 322-328.
- Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial. Annals of Internal Medicine 2013, 159(4), 253-261.
- Hilkens CMU, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?. Clinical & Experimental Immunology 2013, 172(2), 148-157.
- Cooles FA, Isaacs JD, Anderson AE. Treg Cells in Rheumatoid Arthritis: An Update. Current Rheumatology Reports 2013, 15(9), 1-9.
- Sherlock JP, Filer AD, Isaacs JD, Buckley CD. What can rheumatologists learn from translational cancer therapy?. Arthritis Research & Therapy 2013, 15(3), 114.
- Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens C, Young DA, Isaacs JD. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly anti-citrullinated peptide antibody-negative disease. Annals of the Rheumatic Diseases 2012, 71(8), 1374-1381.
- Pratt AG, Brown PM, Cockell SJ, Wilson G, Isaacs JD. A CD4+T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis. In: Annual Scientific Meeting of the American College of Rheumatology (ACR). 2012, Washington, DC, USA: John Wiley & Sons, Inc.
- Pratt AG, Lorenzi AR, Wilson G, Platt PN, Isaacs JD. A Pragmatic Musculoskeletal Ultrasound Screening Protocol Does Not Add to a Predictive Algorithm for Persistent Inflammatory Arthritis in a UK Early Arthritis Clinic. In: Annual Scientific Meeting of the American College of Rheumatology (ACR). 2012, Washington, DC, USA: John Wiley & Sons, Inc.
- Pearce SHS, Mitchell AL, Bennett S, King P, Chandran S, Nag S, Chen S, Smith BR, Isaacs JD, Vaidya B. Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease. Journal of Clinical Endocrinology and Metabolism 2012, 97(10), E1927-E1932.
- Bell GM, Anderson AE, Harry RA, Stoop JN, Hilkens CM, Isaacs J, Dickinson A, McColl E. Autologous tolerogenic dendritic cells in rheumatoid arthritis. In: Annual Meeting of the British Society for Rheumatology. 2012, Glasgow, UK: Oxford University Press.
- Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, Young-Min S, Isaacs JD. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Research & Therapy 2012, 14(1), R30.
- Robinson JI, Carr IM, Cooper DL, Rashid LH, Martin SG, Emery P, Isaacs JD, Barton A, Wilson AG, Barrettt JH, Morgan AW, BRAGGSS. Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. Human Mutation 2012, 33(4), 741-749.
- Plant D, Ibrahim I, Lunt M, Eyre S, Flynn E, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A, BRAGGGSS. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Research & Therapy 2012, 14(5), R214.
- Deehan DJ, Dowen DJ, Sprowson AP, Ferguson LC, Prathalingam NS, Isaacs JD, Birch MA, Oldershaw RA. Differential Release of Heterogeneous Human Mesenchymal Stem Cell Populations from Haemarthrotic Traumatic Knee Injury. American Journal of Stem Cell Research 2012, 1(1), 1-8.
- Raftery G, He JB, Pearce R, Birchall D, Newton JL, Blamire AM, Isaacs JD. Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Research & Therapy 2012, 14(6), R263.
- Cooper DL, Martin SG, Robinson JI, Mackie SL, Charles CJ, Nam J, Isaacs JD, Emery P, Morgan AW, YEAR Consortium. Fc gamma RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy. PLoS One 2012, 7(1), e28918.
- Collerton J, Martin-Ruiz C, Davies K, Hilkens CM, Isaacs J, Kolenda C, Parker C, Dunn M, Catt M, Jagger C, von Zglinicki T, Kirkwood TB. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. Mechanisms of Ageing and Development 2012, 133(6), 456-466.
- Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD. Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology 2012, 51(8), 1397-1406.
- Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A, Biol Rheumatoid Arthrit Genetics. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis and Rheumatism 2012, 64(3), 665-670.
- Pratt AG, Swan D, Richardson S, Wilson G, Hilkens C, Young D, Isaacs JD. A Transcriptional Profile Present in CD4+T-Cells of Patients with Undifferentiated Arthritis Predicts the Future Development of Seronegative Rheumatoid Arthritis and Implicates IL-6 in Disease Evolution. In: Arthritis & Rheumatism: 75th Annual Scientific Meeting of the American College of Rheumatology. 2011, Chicago, Illinois, USA: John Wiley & Sons, Inc.
- Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Practice & Research: Clinical Rheumatology 2011, 25(4), 549-567.
- Bell GM, Reynolds G, Isaacs JD. Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nature Reviews Rheumatology 2011, 7(9), 507-516.
- Isaacs JD, Harari O, Kobold U, Bernasconi C, Lee JS. Effect of Tocilizumab on Hematologic Markers Implicates Interleukin-6 Signaling in the Anemia of Rheumatoid Arthritis. In: Arthritis & Rheumatism: 75th Annual Scientific Meeting of the American College of Rheumatology. 2011, Chicago, Illinois, USA: John Wiley & Sons, Inc.
- Atchia I, Kane D, Reed MR, Isaacs JD, Birrell F. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Annals of the Rheumatic Diseases 2011, 70(1), 110-116.
- Cooles FAH, Jackson GH, Menon G, Isaacs JD. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology 2011, 50(4), 810-812.
- Coulthard LR, Taylor JC, Eyre S, Robinson JI, Wilson AG, Isaacs JD, Hyrich K, Emery P, Barton A, Barrett JH, Morgan AW, McDermott MF. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Annals of the Rheumatic Diseases 2011, 70(1), 98-103.
- Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A, British Soc Rheumatology Biol. Genome-Wide Association Study of Genetic Predictors of Anti-Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations With Polymorphisms at Seven Loci. Arthritis & Rheumatism 2011, 63(3), 645-653.
- Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Research & Therapy 2011, 13(5), R141.
- Cooles FAH, Isaacs JD. Pathophysiology of rheumatoid arthritis. Current Opinion in Rheumatology 2011, 23(3), 233-240.
- Cooles FAH, Pratt AG, Wilson G, Isaacs JD, Ng WF. Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months. Clinical Rheumatology 2011, 30(8), 1137-1138.
- Pratt AG, Charles PJ, Chowdhury M, Wilson G, Venables PJ, Isaacs JD. Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Annals of the Rheumatic Diseases 2011, 70(11), 2056-2058.
- Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Annals of the Rheumatic Diseases 2011, 70(1), 4-7.
- Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Hejide D, van Vollenhoven RF, Emery P. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2011, 70, 909-920.
- Cunnington J, Marshall N, Hide G, Bracewell C, Isaacs J, Platt P, Kane D. A randomized, double-blind, controlled study of ultrasound-guided corticosteroid injection into the joint of patients with inflammatory arthritis. Arthritis & Rheumatism 2010, 62(7), 1862-1869.
- Potter C, Cordell HJ, Barton A, Daly AK, Hyrich K, Mann D, Morgan A, Wilson AG, and the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs J. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFĸB signalling pathways. Annals of the Rheumatic Diseases 2010, 69(7), 1315-1320.
- Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. International Reviews of Immunology 2010, 29(2), 156-183.
- Robinson JI, Barrett JH, Taylor JC, Naven M, Corscadden D, Barton A, Wilson AG, Emery P, Isaacs JD, Morgan AW, YEAR Consortium, BRAGGSS. Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Annals of the Rheumatic Diseases 2010, 69(6), 1054-1057.
- Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases 2010, 69(9), 1629-1635.
- Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69(11), 2042-2050.
- Hassan B, Maxwell JR, Hyrich KL, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology 2010, 49(1), 43-47.
- Tan RJL, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A, BRAGGSS. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases 2010, 69(6), 1029-1035.
- Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CMU. Low-strength T-cell activation promotes Th17 responses. Blood 2010, 116(23), 4829-4837.
- Potter C, Gibbons LJ, Bowes JD, Cordell HJ, Hyrich K, Isaacs JD, Morgan AW, Wilson AG, Barton A, Biol Rheumatoid Arthrit Genetics Group. Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenetics and Genomics 2010, 20(5), 338-341.
- Tudhope SJ, von Delwig A, Falconer J, Pratt A, Woolridge T, Wilson G, Isaacs JD, Ng WF. Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Annals of the Rheumatic Diseases 2010, 69(10), 1873-1879.
- Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AHM, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedren S, Ding B, Guiducci C, Wolbink GJ, Crusius JBA, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TWJ, Tak PP, Bridges SL, Toes REM, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM, Biol Rheumatoid Arthrit Genet & Ge. Rheumatoid Arthritis Risk Allele PTPRC Is Also Associated With Response to Anti-Tumor Necrosis Factor alpha Therapy. Arthritis & Rheumatism 2010, 62(7), 1849-1861.
- Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all?. Nature Reviews Immunology 2010, 10(8), 605-611.
- Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CMU. Therapeutic Effect of Tolerogenic Dendritic Cells in Established Collagen-Induced Arthritis Is Associated With a Reduction in Th17 Responses. Arthritis & Rheumatism 2010, 62(12), 3656-3665.
- Isaacs JD, Chinnery PF. Translating cutting edge science into novel and effective therapies. Current Opinion in Pharmacology 2010, 10(3), 300-301.
- Cooles FAH, Isaacs JD. Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases. Best Practice & Research: Clinical Rheumatology 2010, 24(4), 497-511.
- Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CMU. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Annals of the Rheumatic Diseases 2010, 69(6), 1200-1207.
- Lakey RL, Morgan TG, Rowan AD, Isaacs JD, Cawston TE, Hilkens CM. A novel paradigm for dendritic cells as effectors of cartilage destruction. Rheumatology 2009, 48(5), 502-7.
- Radbruch A, Isaacs J. Animal models in infection and inflammation - Chance and necessity. European Journal of Immunology 2009, 39(8), 1991-1993.
- Isaacs JD. Antibody engineering to develop new antirheumatic therapies. Arthritis Research & Therapy 2009, 11(3), 225.
- Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DPM, Thomson W, Worthington J, Emery P, Morgan AW, Wilson AG, Isaacs J, Barton A, BRAGGSS. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Annals of the Rheumatic Diseases 2009, 68(1), 69-74.
- Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 2009, 9(7), 909-919.
- Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Practice & Research: Clinical Rheumatology 2009, 23(1), 37-48.
- Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW, Wilson AG, Isaacs JD, Worthington J, Barton A, BRAGGSS. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenetics and Genomics 2009, 19(4), 319-323.
- Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, Robinson JH, Isaacs JD, Hilkens CM. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. Journal of Leukocyte Biology 2009, 85(2), 243-250.
- Atchia I, Kane D, Reed MR, Isaacs J, Birrell F. Musculoskeletal ultrasound predicts predicts response to corticosteroid injection in moderate-severe hip osteoarthritis. In: Rheumatology: Annual Meeting of the British Society of Rheumatology. 2009, Glasgow, UK: Oxford University Press.
- Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Current Opinion in Hematology 2009, 16(4), 274-279.
- Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Expert Opinion on Biological Therapy 2009, 9(12), 1463-1475.
- Lorenzi A, Morgan TA, Anderson A, Catterall J, Patterson AM, Foster HE, Isaacs JD. Thymic function in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2009, 68(6), 983-900.
- Moots RJ, Ostor AJK, Isaacs JD. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?. Expert Opinion on Investigational Drugs 2009, 18(11), 1687-1699.
- Morgan AW, Hale G, Rebello PRUB, Richards SJ, Gooi H-C, Waldmann H, Emery P, Isaacs JD. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM: An International Journal of Medicine 2008, 101(4), 299-306.
- Burgoyne CH, Field SL, Brown AK, Hensor EM, English A, Bingham SL, Verburg R, Fearon U, Lawson CA, Hamlin PJ, Straszynski L, Veale D, Conaghan P, Hull MA, van Laar JM, Tennant A, Emery P, Isaacs JD, Ponchel F. Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Annals of the Rheumatic Diseases 2008, 67(6), 750-757.
- Thompson B, Corris P, Miller JA, Cooper RG, Halsey JP, Isaacs JD. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. Journal of Rheumatology 2008, 35(10), 2080-2082.
- Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG. Association of the tumour necosis factor -308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human Molecular Genetics 2008, 17(22), 3532-3538.
- Lorenzi AR, Patterson AM, Pratt A, Jefferson M, Chapman CE, Ponchel F, Isaacs JD. Determination of thymic function directly from peripheral blood: a validated modification to an established method. Journal of Immunological Methods 2008, 339(2), 185-94.
- Anderson AE, Sayers BL, Haniffa MA, Swan DJ, Diboll J, Wang XN, Isaacs JD, Hilkens CMU. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. Journal of Leukocyte Biology 2008, 84(1), 124-133.
- Lorenzi A, Clarke A, Wooldridge T, Waldmann H, Hale G, Symmons D, Hazleman B, Isaacs J. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes. Arthritis & Rheumatism 2008, 58(2), 370-375.
- Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw K, Bingham SJ, Bejarano V, Isaacs JD, Emery P. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology 2008, 47(10), 1469-1475.
- Isaacs J. Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future. Rheumatology 2008, 47(10), 1461-1468.
- Lorenzi AR, Foster HE, Isaacs JD. Thymic function and immune senescence in juvenile idiopathic arthritis. Arthritis & Rheumatism 2008, 60(1), 310-311.
- Anderson AE, Sayers BL, Swan DJ, Isaacs JD, Hilkens CM. Tolerogenic dendritic cell therapy for rheumatoid arthritis. In: BSR Annual Meeting and BHPR Spring Meeting. 2008, Liverpool: Oxford University Press.
- Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP. Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells. Journal of Immunology 2007, 179(3), 1595-1604.
- Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: Lessons learned, future directions. Nature Reviews Drug Discovery 2007, 6(1), 75-92.
- Sayers B, Haniffa M, Diboll J, Isaacs J, Hilkens C. Generation of dexamethasone and vitamin D3-treated human monocyte-derived dendritic cells with tolerogenic properties. In: Arthritis Research & Therapy: 6th Global Arthritis Research Network Meeting (GARN). 2007, Zurich, Switzerland: BioMed Central Ltd.
- Isaacs JD. T cell immunomodulation-the Holy Grail of therapeutic tolerance. Current Opinion in Pharmacology 2007, 7(4), 418-425.
- Von Delwig A, Altmann DM, Charlton FG, McKie N, Isaacs JD, Holmdahl R, Robinson JH. T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice. Annals of the Rheumatic Diseases 2007, 66(5), 599-604.
- Morgan AW, Robinson JI, Barrett JH, Martin J, Walker A, Babbage SJ, Ollier WER, Gonzalez-Gay MA, Isaacs JD. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Research & Therapy 2006, 8(4), R109.
- Lawson CA, Brown AK, Bejarano V, Douglas SH, Burgoyne CH, Greenstein AS, Boylston AW, Emery P, Ponchel F, Isaacs JD. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology 2006, 45(10), 1210-1217.
- von Delwig A, Wilson AJ, Altmann DM, Holmdahl R, Harding CV, Mckie N, Isaacs JD, Lakey JH, Robinson JH. Febrile temperatures enhance antigen processing of type II collagen for presentation to CD4 T cells. Arthritis & Rheumatism 2006, 54(9), S639-S639.
- von Delwig A, Hilkens CM, Altmann DM, Holmdahl R, Isaacs JD, Harding CV, Robertson H, McKie N, Robinson JH. Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. Arthritis Research & Therapy 2006, 8(4), R93.
- Von Delwig A, Altmann DM, Isaacs JD, Harding CV, Holmdahl R, Balfour-McKie JN, Robinson JH. The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis and Rheumatism 2006, 54(2), 482-491.
- Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. Journal of Immunology 2005, 175(2), 1257-1266.
- Morgan AW, Barrett JH, Griffiths B, Subramanian D, Robinson JI, Keyte VH, Ali M, Jones EA, Old RW, Ponchel F, Boylston AW, Situnayake RD, Markham AF, Emery P, Isaacs JD. Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Research & Therapy 2005, 8(1), R5.
- Lawson CA, Donaldson IJ, Bowman SJ, Shefta J, Morgan AW, Gough A, Isaacs JD, Griffiths B, Emery P, Pease CT, Boylston AW. Analysis of the insertion/deletion related polymorphism within T cell antigen receptor β variable genes in primary Sjögren's syndrome. Annals of the Rheumatic Diseases 2005, 64(3), 468-470.
- Morgan AW, Gonzalez-Gay MA, Robinson JI, Babbage SJ, Haroon-Rashid L, Hajeer AH, Ollier WER, Isaacs JD. Association of FCGR2A and FC gamma R haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis. In: Rheumatology: Third International Conference on Giant Cell Arteritis and Polymyalgia Rheumatica. 2005, Cambridge, UK: Oxford University Press.
- Ryan KR, Lawson CA, Lorenzi AR, Arkwright PD, Isaacs JD, Lilic D. CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy [1]. Journal of Allergy and Clinical Immunology 2005, 116(5), 1158-1159.
- Verburg RJ, Flierman R, Sont JK, Ponchel F, Van Dreunen L, Levarht EW, Welling MM, Toes REM, Isaacs JD, Van Laar JM. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Annals of the Rheumatic Diseases 2005, 64(10), 1397-1405.
- Isaacs JD, Thiel A. Immune reconstitution. Best Practice and Research: Clinical Haematology 2004, 17(2), 345-358.
- Ponchel F, Verburg RJ, Bingham SJ, Brown AK, Moore J, Protheroe A, Short K, Lawson CA, Morgan AW, Quinn M, Buch M, Field SL, Maltby SL, Masurel A, Douglas SH, Straszynski L, Fearon U, Veale DJ, Patel P, McGonagle D, Snowden J, Markham AF, Ma D, van Laar JM, Papadaki HA, Emery P, Isaacs JD. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research & Therapy 2004, 7(1), R80-R92.
- Isaacs JD, Clarke AM, Hazleman BL, Hale G, Waldmann H, Symmons DPM. Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis. In: Arthritis & Rheumatism: 68th Annual Scientific Meeting of the American College of Rheumatology. 2004, San Antonio, Texas, USA: John Wiley & Sons, Inc.
- Isaacs JD, Emery P. Targeting B cells with rituximab: An effective and well tolerated treatment for active rheumatoid arthritis (RA). In: Rheumatology: British Society for Rheumatology Annual Meeting. 2004, Edinburgh, UK: Oxford University Press.
- Ponchel F, Brown AK, Lawson CA, Douglas SH, Emery P, Isaacs JD. CD4+T-Cell TREC-Content in RA Patients in Clinical Remission. Rheumatology 2003, 42(S1), 127.
- Conaghan PG, O'Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, Quinn M, Karim Z, Green MJ, Proudman S, Isaacs J, Emery P. Elucidation of the relationship between synovitis and bone damage. A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis & Rheumatism 2003, 48(1), 64-71.
- Morgan AW, Keyte VH, Babbage SJ, Robinson JI, Ponchel F, Barrett JH, Bhakta BB, Bingham SJ, Buch MH, Conaghan PG, Gough A, Green M, Lawson CA, Pease CT, Markham AF, Ollier WER, Emery P, Worthington J, Isaacs JD. FcγRIIIA‐158V and rheumatoid arthritis: a confirmation study. Rheumatology 2003, 42(4), 528-533.
- Ponchel F, Papadaki H, Bingham SJ, Protheroe A, Douglas SH, Emery P, Isaacs JD. IL-7 Deficiency and Prolonged Therapy-Induced Lymphopenia in Rheumatoid Arthritis. Rheumatology 2003, 42(S1), 127.
- Ali M, Veale DJ, Reece RJ, Quinn M, Henshaw K, Zanders ED, Markham AF, Emery P, Isaacs JD. Overexpression of transcripts containing LINE-1 in the synovia of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2003, 62(7), 663-666.
- Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 2003, 42, 235-239.
- Ponchel F, Toomes C, Bransfield K, Leong FT, Field SL, Douglas SH, Bell SM, Combaret V, Puisieux A, Mighell AJ, Robinson PA, Inglehearn CF, Isaacs JD, Markham AF. Real-time PCR based on SYBR-green flourescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnology 2003, 3, 18.
- Lawson CA, Brown AK, Greenstein A, Douglas SH, Boylston AW, Emery P, Ponchel F, Isaacs JD. Rheumatoid Arthritis is Associated With A Deficit in the CD4(+)CD25(high) Regulatory T Cell Population in Peripheral Blood. Rheumatology 2003, 42(S1), 125-126.
- Ponchel F, Brown AK, Lawson CA, Buch M, Douglas SD, Emery P, Isaacs JD. THE EXPRESSION OF THE JAGGED/NOTCH SIGNALING PATHWAY IS ABNORMAL IN RHEUMATOID ARTHRITIS AND DOES NOT NORMALIZE IN PATIENTS IN CLINICAL REMISSION. In: RHEUMATOLOGY. 2003, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS.
- Ponchel F, Morgan AW, Bingham SJ, Quinn M, Buch M, Verburg RJ, Henwood JA, Douglas SH, Masurel A, Conaghan P, Gesinde M, Taylor J, Markham AF, Emery P, van Laar JM, Isaacs JD. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002, 100(13), 4550-4556.
- Bingham S, Veale D, Fearon U, Isaacs JD, Morgan G, Emery P, McGonagle D, Reece R, Clague R, Snowden JA. High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis & Rheumatism 2002, 46(3), 837-839.
- Bingham SJ, Snowden J, McGonagle D, Richards S, Isaacs J, Morgan G, Emery P. Autologous stem cell transplantation for rheumatoid arthritis – interim report of six patients. The Journal of Rheumatology 2001, S64, 21-24.
- Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 2001, 98(9), 2736-2744.
- Ali M, Ponchel F, Wilson K, Francis MJD, Wu X, Verhoeff A, Boylston AW, Veale DJ, Emery P, Markham AF, Lamb JR, Isaacs JD. Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy. The Journal of Clinical Investigation 2001, 107(4), 519-528.
- Finlayson NDC, Tomlinson S, Weetman AP, Connell JMC, Hill AVS, Savage CO, Wiles CM, Williams B, Ireland J, Vallance P, Whyte M, Seckl JR, Jung R, McKillop JH, Stout RW, Atkinson AB, Tomkin GH, Adgey AAJ, Axon ATR, Beck P, Eastwood JB, Fitzgerald M, Godman MJ, Heath DA, Kendall MJ, MacGregor GA, Petrie JC, Ell RGG, Allan RN, Barry RE, Boulton Jones JM, Evans CC, George CF, Heading RC, Jewell DP, Lazarus JH, Parker AC, Rawlins MD, Thurston H, Cappuccio FP, Conlon CP, John CS, Dornhurst A, Douglas JG, Elborn JS, El-Omar E, Friedland JS, Gilks CF, Groves RW, Hall AS, Hawkey CJ, Hillhouse E, Hughes J, Isaacs J, Jardine AG, Jodrell DI, Jones DEJ, Monson JP, Price P, Pugh CW, Ray DW, Santis G, Satsangi J, Scott DGI, Scott DL, Vickers MA, Wardlaw A. The ninety-fifth annual general meeting of the association of physicians of Great Britain and Ireland 2001. In: The ninety-fifth annual general meeting of the association of physicians of Great Britain and Ireland. 2001, Edinburgh: Oxford University Press.
- Morgan AW, Griffiths B, Ponchel F, Montague BMN, Ali M, Gardener PP, Gooi H-C, Situnayake RD, Markham AF, Emery P, Isaacs JD. Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis & Rheumatism 2000, 43(10), 2328-2334.
- Wakefield RJ, Gibbon WW, Conaghan PG, OConnor P, McGonagle D, Pease C, Green MJ, Veale DJ, Isaacs JD, Emery P. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis and Rheumatisim 2000, 43(12), 2762-2770.
- Proudman SM, Conachan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, Wakefield RJ, Reece RJ, Miles S, Adebajo A, Gough A, Helliwell P, Martin M, Huston G, Pease C, Veale DJ, Isaacs J, Heijde vanderDMFM, Emery P. Treatment of poor-prognosis early rheumatoid arthritis - A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis & Rheumatism 2000, 43(8), 1809-1819.